CD30, TNF-receptor superfamily member, is a receptor for TNFSF8/CD30L. TRAF2 and TRAF5 can interact with this receptor and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and it also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.CD30 is expressed in mononuclear Hodgkin’s and multinucleated Reed-Sternberg cells in Hodgkin’s disease, in tumor cells of a majority of anaplastic large cell lymphomas, in a varying proportion of activated T and B cells. In non-lymphoid malignancies, CD30 reactivity has been reported in embryonal carcinomas (ECs), seminomas, and hepatocellular carcinomas.This antibody has been useful in identifying Hodgkin's lymphoma, anaplastic large cell lymphomas (ALCL) and primary cutaneous CD30+ T-cell lymphoproliferative disorders.
Synthetic peptide corresponding to CD30 residues within aa495‐C terminal of CD30 was used as an immunogen.
1.Watanabe M., et al. Am J Pathol. 2003 Aug;163(2):633-41
2.Pileri SA., et al. J Clin Pathol. 2002 Mar;55(3):162-76.